Advice
UK Conditional Marketing Authorisation withdrawn
On 10 January, 2024, the UK Conditional Marketing Authorisation for crizanlizumab (Adakveo) was revoked.
Medicine details
- Medicine name:
- crizanlizumab (Adakveo)
- SMC ID:
- SMC2438
- Indication:
Prevention of recurrent vaso-occlusive crises (VOC) in sickle cell disease (SCD) patients aged 16 years and older, as either an add-on therapy to hydroxyurea/hydroxycarbamide (HC/HU) or as monotherapy in patients for whom HC/HU is inappropriate or inadequate.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Withdrawn
- Date advice published
- 11 July 2022
Additional notes
On 10 January, 2024, the UK Conditional Marketing Authorisation for crizanlizumab (Adakveo) was revoked due to lack of therapeutic efficacy as determined by MHRA.